Algert Global LLC Sells 2,410 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)

Algert Global LLC reduced its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 2.5% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 94,960 shares of the company’s stock after selling 2,410 shares during the quarter. Algert Global LLC’s holdings in Dyne Therapeutics were worth $3,411,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Sei Investments Co. acquired a new position in Dyne Therapeutics in the 1st quarter valued at about $693,000. Vanguard Group Inc. grew its position in shares of Dyne Therapeutics by 47.7% in the first quarter. Vanguard Group Inc. now owns 3,440,270 shares of the company’s stock valued at $97,669,000 after purchasing an additional 1,110,629 shares during the last quarter. American International Group Inc. increased its stake in shares of Dyne Therapeutics by 31.8% during the first quarter. American International Group Inc. now owns 29,138 shares of the company’s stock worth $827,000 after purchasing an additional 7,027 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in Dyne Therapeutics by 8,284.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,132,092 shares of the company’s stock worth $32,141,000 after purchasing an additional 1,118,590 shares during the last quarter. Finally, Janus Henderson Group PLC boosted its stake in Dyne Therapeutics by 23,512.0% in the 1st quarter. Janus Henderson Group PLC now owns 2,675,240 shares of the company’s stock valued at $75,915,000 after purchasing an additional 2,663,910 shares during the period. 96.68% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CEO John Cox bought 32,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 4th. The shares were acquired at an average cost of $33.04 per share, with a total value of $1,057,280.00. Following the completion of the purchase, the chief executive officer now directly owns 8,000 shares in the company, valued at $264,320. The trade was a -133.33 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Carlo Incerti sold 16,500 shares of Dyne Therapeutics stock in a transaction on Monday, November 18th. The shares were sold at an average price of $28.73, for a total transaction of $474,045.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 176,257 shares of company stock worth $6,193,718. 20.77% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several research analysts have weighed in on DYN shares. Piper Sandler reiterated an “overweight” rating and set a $53.00 price objective on shares of Dyne Therapeutics in a research report on Monday, September 23rd. Guggenheim boosted their price objective on shares of Dyne Therapeutics from $45.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, August 15th. StockNews.com cut shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 16th. Chardan Capital reiterated a “buy” rating and issued a $50.00 price target on shares of Dyne Therapeutics in a research note on Wednesday, November 13th. Finally, Oppenheimer restated an “outperform” rating and set a $55.00 price objective on shares of Dyne Therapeutics in a research note on Tuesday, September 3rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $51.40.

Dyne Therapeutics Stock Performance

Dyne Therapeutics stock opened at $29.45 on Tuesday. The stock has a fifty day moving average of $32.06 and a 200-day moving average of $35.40. The stock has a market capitalization of $3.00 billion, a P/E ratio of -8.27 and a beta of 1.10. Dyne Therapeutics, Inc. has a 52 week low of $10.12 and a 52 week high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.25). On average, research analysts forecast that Dyne Therapeutics, Inc. will post -3.45 earnings per share for the current year.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.